On September 21, PHARMARON rose 3.25% in regular trading, trading at HK$30.48/share, with turnover of HK$101 million. The stock opened near HK$29.70 and climbed steadily during the session amid broad-based strength across the CRO sector.
Multiple catalysts are driving the rally. Novo Nordisk and Anthropic announced an AI-powered drug discovery collaboration using the Claude Science platform, reinforcing optimism around AI-enabled pharmaceutical R&D. Meanwhile, China's domestic innovative drug out-licensing transaction volume has surpassed US$120 billion, signaling robust R&D funding flows that support a volume-and-price upsurge in CRO order books. Additionally, ten Chinese government departments recently issued a joint policy statement supporting innovative drug development, extending a favorable policy backdrop for the sector.
On the brokerage side, Goldman Sachs has reiterated a Buy rating on China's CRO/CDMO sector recovery, while Daiwa, Bank of America, and Morgan Stanley have raised their target prices for PHARMARON to HK$38.5, HK$38.4, and HK$35.6, respectively. The company reported first-half revenue growth of 17.92% year-over-year with new order growth exceeding 30%, and recently completed a RMB 2.18 billion zero-coupon convertible bond issuance to strengthen its balance sheet.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments